Ibritumomab tiuxetan

Source: Wikipedia, the free encyclopedia.
Ibritumomab tiuxetan
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetCD20
Clinical data
Trade namesZevalin
AHFS/Drugs.comMonograph
License data
intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
ChEMBL
 ☒NcheckY (what is this?)  (verify)

Ibritumomab tiuxetan (pronounced

methyl group.[2][3]

Medical use

Ibritumomab is used to treat relapsed or refractory, low grade or transformed

first-line chemotherapy.[4] The treatment should not be administered to patients with ≥25% lymphoma marrow involvement and/or impaired bone marrow reserve.[5]

The treatment starts with an infusions of rituximab. This may be followed by an administration of

platelet count.[6]

Mechanism of action

The antibody binds to the

lymphoid stem cells.[7]

History

Developed by the IDEC Pharmaceuticals, now part of

refractory CD20+ follicular B-cell non-Hodgkin's lymphoma.[10]

In September 2009, ibritumomab received approval from the FDA for an expanded label to include previously untreated patients with a chemotherapy response.[4]

Availability

Ibritumomab is currently under patent protection and not available in generic form. When first approved, it was the most expensive drug available given in a single dose, costing over US$37,000 (€30,000) for the average dose.[11][12] However, ibritumomab is essentially an entire course of lymphoma therapy which is delivered in 7–9 days, with one visit for pre-dosing Rituxan, and one visit a week later for the actual Zevalin therapeutic dose preceded by Rituxan. Compared to other monoclonal antibody treatments (many of which are well over US$40,000 for a course of therapy), it may be considered cost effective.[11][13]

See also

  • Tositumomab, an alternative radioimmunotherapy treatment for non-Hodgkin's lymphoma.

External links

References

  1. ^ "Ibritumomab Tiuxetan". National Cancer Institute. 26 February 2008. Retrieved 25 July 2020.
  2. S2CID 22166498
    .
  3. ^ WHO Drug Information
  4. ^
    PMID 21536931
    .
  5. ^ "Zevalin package insert" (PDF). Acrotech Biopharma. September 2019.
  6. S2CID 8951564
    .
  7. ^ "Ibritumomab Tiuxetan" (PDF). US Food and Drug Administration.
  8. ^ Pollack A (24 June 2003). "Idec to Merge With Biogen in $6.8 Billion Deal". The New York Times.
  9. S2CID 20940701
    .
  10. ^ "Zevalin". European Medicines Agency. 17 September 2018. Retrieved 25 July 2020.
  11. ^
    S2CID 201758449
    .
  12. ^ Bazell R (23 June 2004). "Why are the new cancer drugs so expensive?". Slate Magazine.
  13. PMID 25773554
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ibritumomab_tiuxetan&oldid=1167527790"